An Educational Guide to MDMA Research, PTSD, Complex Trauma, Social Anxiety, Depression, Neuroscience and Clinical Safety
Last updated: 18 November 2026
Educational and scientific information only.
MDMA-assisted therapy has become an important subject of modern psychiatric and neuroscientific research. Universities, medical institutions and independent researchers are investigating whether MDMA, combined with structured psychotherapy, may have clinical applications for certain mental health conditions.
Much of the research has concentrated on post-traumatic stress disorder (PTSD), although studies are increasingly examining social anxiety, depression and other psychiatric conditions.
The science is developing, and important questions about clinical effectiveness, long-term outcomes, safety and appropriate regulation remain unresolved.
This frequently asked questions guide explains what researchers currently know, what remains uncertain and how MDMA-assisted psychotherapy is studied.
The information is intended exclusively for educational and scientific purposes. It does not encourage the use of MDMA or other psychoactive substances, recommend treatment, or make claims that MDMA can cure or prevent any medical or psychiatric condition.
1. Understanding MDMA and MDMA-Assisted Psychotherapy
What is MDMA?
MDMA stands for 3,4-methylenedioxymethamphetamine, a synthetic psychoactive substance that affects several neurotransmitter systems in the brain.
It is commonly classified as an entactogen or empathogen because its subjective effects can include altered emotional awareness, feelings of interpersonal connection and changes in social perception.
MDMA also has stimulant properties and can influence heart rate, blood pressure and body temperature.
What does MDMA-assisted therapy mean?
In scientific research, MDMA-assisted therapy refers to the administration of pharmaceutical-grade MDMA within a structured psychological treatment protocol.
These research protocols commonly include participant screening, preparation, monitored experimental sessions and psychological integration afterwards.
The substance is studied as one component of a broader intervention.
MDMA-assisted psychotherapy should therefore not be confused with recreational MDMA use or unsupervised psychoactive experiences.
Is MDMA a classical psychedelic?
No.
Classical psychedelics, including psilocybin and LSD, produce many of their characteristic effects primarily through serotonin 5-HT2A receptor activation.
MDMA has a different primary pharmacological mechanism.
It increases the availability of several neurotransmitters, particularly serotonin, noradrenaline and dopamine.
MDMA is generally classified as an entactogen rather than a classical psychedelic, although the substance may produce some overlapping subjective experiences.
How does MDMA affect the brain?
MDMA primarily acts on monoamine transporter systems.
Its effects involve increased extracellular concentrations of serotonin, noradrenaline and dopamine.
Researchers are investigating how these changes influence emotional responses, fear-related processing, social perception and autobiographical memory.
The relationship between these acute effects and any lasting psychological changes remains an active scientific question.
Does MDMA increase empathy?
Some experimental studies have reported changes in emotional empathy, interpersonal warmth and social connectedness following MDMA administration.
However, the effects depend on the individual, research setting and measurement method.
Increased feelings of empathy do not necessarily mean that someone's social judgement becomes more accurate or that lasting interpersonal improvements will occur.
Why is MDMA called an empathogen?
The term empathogen refers to substances that may produce subjective feelings of empathy or emotional connectedness.
Entactogen is another term commonly used in the scientific literature, referring to experiences involving greater awareness of internal emotions.
These terms describe characteristic subjective effects, not proven clinical benefits.
Is MDMA-assisted therapy the same as taking ecstasy?
No.
Ecstasy is a common street name for recreational products that may contain MDMA, other psychoactive compounds or combinations of substances.
Clinical studies use substances with defined identity, purity and quality controls.
Research protocols also involve participant selection, monitoring and structured psychological procedures.
Consequently, conclusions from controlled clinical studies cannot be directly applied to recreational drug use.
Is pharmaceutical-grade MDMA different from street MDMA?
The active molecule may be chemically identical when a street product genuinely contains MDMA.
However, pharmaceutical-grade material has controlled specifications for identity, purity and manufacturing quality.
Unregulated products may contain unexpected substances or variable concentrations.
These differences are important when interpreting clinical research and assessing safety.
2. What Happens in MDMA Clinical Research?
How is MDMA-assisted psychotherapy studied?
Clinical trials generally follow a defined protocol consisting of preparation, monitored substance-administration sessions and integration.
Participants are screened against medical and psychiatric criteria.
Researchers document outcomes using validated questionnaires, clinical assessments and safety monitoring.
The specific design differs between trials.
What is psychological preparation in MDMA research?
Preparation is used to establish a therapeutic relationship, discuss expectations and explain the research procedure.
Participants may explore their personal history, relevant symptoms, emotional concerns and the possible challenges of the experience.
Preparation also includes discussion of professional boundaries, informed consent and potential adverse effects.
What is intention setting?
Intention setting involves identifying themes or questions that participants may wish to explore during an experimental session.
In research settings, this may be incorporated into the psychological preparation.
Intentions do not guarantee particular experiences or outcomes.
The purpose is to provide orientation without imposing a predetermined psychological result.
What happens during an MDMA research session?
During controlled research, participants receive the investigational substance under supervision.
Researchers or therapists remain available according to the study protocol.
The environment may include comfortable seating or bedding, quiet surroundings and music.
Participants may spend periods reflecting internally or discussing experiences with the research team.
Medical and psychological monitoring procedures depend on the specific trial.
How long do experimental MDMA sessions last?
Many published MDMA-assisted psychotherapy protocols have involved experimental sessions lasting approximately six to eight hours.
The exact duration depends on the research design.
This does not include all preparation, monitoring and follow-up appointments associated with participation in a clinical trial.
Why is music sometimes used in MDMA research?
Music can influence emotional experiences and the overall atmosphere.
Some psychedelic-assisted research protocols incorporate music to support introspection or provide a structured environment.
However, the specific contribution of music to clinical outcomes remains difficult to separate from other components of the intervention.
What is psychological integration after MDMA research?
Integration refers to structured reflection following an experimental session.
Participants may discuss emotions, memories, observations and personal interpretations that emerged during the experience.
The objective is to consider the experience within the broader psychological process.
Integration is a common component of clinical protocols, but its independent contribution to treatment outcomes remains under investigation.
Why do researchers combine MDMA with psychotherapy?
The scientific hypothesis is that MDMA's temporary effects on emotional and social processing might influence engagement with certain psychotherapeutic procedures.
Researchers are examining whether these effects interact with mechanisms involving avoidance, emotional learning or memory processing.
The extent to which psychological support contributes independently to observed clinical outcomes remains an important research question.
Is physical contact part of MDMA-assisted psychotherapy?
Physical contact is not a necessary component of MDMA-assisted psychotherapy.
Professional boundaries, participant autonomy and informed consent are particularly important because psychoactive substances may alter perception, vulnerability and interpersonal feelings.
Any clinical research protocol should define clear procedures regarding touch, consent, safeguarding and professional conduct.
Consent should never be assumed or treated as a reason to disregard established professional boundaries.
Can MDMA research participants experience difficult emotions?
Yes.
Altered emotional processing can involve distressing memories, uncomfortable sensations or challenging psychological experiences.
MDMA does not guarantee feelings of comfort, trust or emotional safety.
Clinical studies therefore use screening, preparation and monitoring procedures to assess and manage relevant risks.
3. MDMA Research and Post-Traumatic Stress Disorder
Why is MDMA being studied for PTSD?
PTSD can involve intrusive memories, avoidance, hyperarousal and changes in mood or beliefs following traumatic experiences.
Researchers are investigating whether MDMA's effects on emotional processing and fear-related responses could influence structured psychotherapeutic interventions.
This is a scientific hypothesis under clinical evaluation.
What did the MAPS studies investigate?
The Multidisciplinary Association for Psychedelic Studies, or MAPS, supported a series of studies investigating MDMA-assisted psychotherapy for PTSD.
These included phase 2 investigations and two large phase 3 trials.
The protocols involved pharmaceutical-grade MDMA, psychological preparation, monitored sessions and integration.
The studies did not investigate the routine use of unregulated MDMA products.
What were the results of the 2023 MDMA PTSD trial?
A phase 3 study published in Nature Medicine in 2023 reported greater average reductions in PTSD symptoms among participants receiving MDMA-assisted therapy than among participants receiving therapy with placebo.
At the study endpoint, approximately 71% of the MDMA group no longer met diagnostic criteria for PTSD, compared with approximately 48% of the placebo group.
These percentages refer to that specific trial and its assessment period.
They do not represent a guaranteed success rate, proof of permanent recovery or evidence that MDMA works equally well for everyone.
What does the latest systematic review say?
A systematic review published in Neuropsychopharmacology in October 2026 evaluated six randomized controlled trials involving 286 participants.
The analysis found greater short-term improvement in PTSD symptom measurements among participants receiving MDMA-assisted therapy compared with control conditions.
However, the researchers rated the overall certainty of the evidence as low.
Important concerns included challenges with blinding, expectancy effects, study conduct and safety reporting.
Does this mean MDMA cures PTSD?
No.
Clinical improvement, remission of diagnostic criteria and permanent recovery are different concepts.
Research findings must be interpreted in relation to study duration, participant characteristics and follow-up methods.
Current evidence does not establish that MDMA provides a permanent cure for PTSD.
3. Complex PTSD, Childhood Trauma and Emotional Processing
Is MDMA being investigated for complex PTSD?
Research involving MDMA-assisted psychotherapy has included people with histories of prolonged or repeated trauma.
Some participants have experienced childhood adversity, interpersonal violence or other complex traumatic circumstances.
However, complex PTSD is a distinct clinical presentation, and the existing evidence does not establish equivalent outcomes for every trauma-related condition.
What is the difference between PTSD and complex PTSD?
PTSD commonly involves intrusive memories, avoidance, hyperarousal and negative changes in mood or cognition.
Complex PTSD additionally involves persistent difficulties in areas such as emotional regulation, self-concept and relationships.
These differences are relevant when designing and evaluating clinical interventions.
Why is emotional processing important in trauma research?
Emotional processing is one of several mechanisms investigated in psychotherapy research.
Researchers examine how people respond to emotionally significant memories, perceived threats and avoidance patterns.
MDMA has attracted scientific interest because of its temporary effects on some of these processes.
However, a proposed mechanism does not automatically establish clinical effectiveness.
Does MDMA change traumatic memories?
Experimental research suggests MDMA may influence aspects of emotional memory and responses to previously learned fear.
Scientists are investigating possible effects on fear extinction and memory reconsolidation.
These processes are complex, and findings from animal studies or laboratory experiments cannot be assumed to translate directly into lasting changes in human traumatic memories.
Can MDMA make difficult memories easier to discuss?
Some participants in controlled studies describe changes in how emotionally significant memories are experienced or discussed.
However, these subjective reports vary.
MDMA can also cause distress, confusion or heightened emotions.
It should not be assumed that difficult memories will become easier to approach for every individual.
Can MDMA recover forgotten childhood memories?
There is no reliable scientific basis for claiming that MDMA can accurately recover forgotten memories.
Human memory is reconstructive and can be influenced by expectations, emotional states and suggestion.
Any memories or interpretations arising during altered states of consciousness require careful handling and should not automatically be regarded as historically accurate.
4. MDMA, Social Anxiety and General Anxiety Research
Is MDMA being researched for social anxiety disorder?
Yes.
A randomized, open-label, waiting-list-controlled trial published in November 2026 investigated MDMA-assisted psychotherapy in 20 participants with social anxiety disorder.
The researchers reported improvements in social anxiety measurements.
However, the study was small, and its design limits the conclusions that can be drawn.
Larger controlled trials are needed.
Why are researchers interested in MDMA and social anxiety?
Social anxiety disorder often involves fear of negative evaluation, rejection or embarrassment.
MDMA can temporarily influence interpersonal perceptions and emotional responses.
Researchers are investigating whether these effects might interact with psychological processes relevant to social anxiety.
This remains an experimental area of research.
Is social anxiety different from general anxiety?
Yes.
Social anxiety disorder primarily involves fear related to social situations and evaluation by others.
Generalized anxiety disorder involves persistent and excessive worry across multiple areas of life.
These are distinct diagnoses, and findings from one condition cannot automatically be applied to another.
Is MDMA being investigated for generalized anxiety disorder?
There is scientific interest in MDMA's effects on anxiety-related processes.
However, evidence specifically supporting MDMA-assisted psychotherapy for generalized anxiety disorder remains limited.
Research involving PTSD or social anxiety does not establish effectiveness for generalized anxiety disorder.
Could MDMA temporarily increase anxiety?
Yes.
Despite its reputation for producing feelings of emotional openness, MDMA can also cause anxiety, agitation or uncomfortable physiological sensations.
Responses differ between individuals.
These possibilities are important considerations in clinical safety research.
Is MDMA being studied for panic disorder?
Research specifically focused on MDMA-assisted psychotherapy for panic disorder remains limited.
There is insufficient evidence to establish its effectiveness or safety for that indication.
Panic disorder should not be treated as interchangeable with other anxiety conditions.
6. MDMA and Depression Research
Is MDMA-assisted psychotherapy being studied for depression?
Yes.
Researchers have begun examining MDMA-assisted psychotherapy in people with major depressive disorder.
A Norwegian proof-of-principle study published in 2025 involved 12 participants with moderate to severe depression.
The study reported changes in depressive symptom measurements.
However, it was small and uncontrolled, so the results are preliminary.
What did the November 2026 depression research examine?
A study published in November 2026 investigated measures of well-being, self-compassion and alexithymia using data from the earlier Norwegian research programme.
Alexithymia refers to difficulty identifying or describing emotions.
These findings contribute to understanding possible psychological mechanisms, but they do not establish MDMA as an effective or approved treatment for depression.
Is MDMA an antidepressant?
MDMA is not classified as a conventional antidepressant.
It has different pharmacological properties from commonly prescribed antidepressant medications.
Although researchers are examining potential psychiatric applications, MDMA should not be considered interchangeable with established antidepressant treatments.
Can MDMA permanently change depressive thought patterns?
Current research does not establish that MDMA produces permanent changes in depressive thinking.
Some early studies have reported changes in psychological measurements after controlled interventions.
The durability, clinical relevance and mechanisms of these observations require further investigation.
Is MDMA being studied for emotional numbness?
Researchers are interested in how MDMA influences emotional awareness and interpersonal experiences.
Some preliminary studies have examined related psychological measurements.
However, emotional numbness can arise from many different causes, and there is insufficient evidence to establish MDMA as an appropriate intervention for this symptom.
6. MDMA Research Beyond PTSD, Anxiety and Depression
Is MDMA being investigated for alcohol use disorder?
Yes.
Researchers have explored MDMA-assisted psychotherapy in relation to alcohol use disorder, including early-stage clinical investigations.
These studies remain preliminary.
They do not establish MDMA as a recognised treatment for alcohol dependence.
Has MDMA been studied in autistic adults?
Yes.
A small earlier pilot study investigated MDMA-assisted psychotherapy for social anxiety in autistic adults.
The findings generated interest in further research, but the study was too small to support broad conclusions.
Autism itself is not a condition that MDMA has been shown to cure or prevent.
Is MDMA being researched for relationship difficulties?
Researchers have investigated MDMA's acute effects on social connection, interpersonal perception and emotional communication.
However, these findings do not establish MDMA-assisted psychotherapy as an effective treatment for relationship difficulties.
Feelings of closeness during substance administration do not necessarily translate into durable relationship changes.
Is MDMA being investigated for end-of-life anxiety?
Early research has explored MDMA-assisted psychotherapy in people experiencing psychological distress associated with serious illness.
The evidence remains limited, and further studies are required.
Clinical findings from these populations should not be generalized to unrelated psychiatric conditions.
Does MDMA increase neuroplasticity?
Some preclinical studies have reported changes in biological processes associated with neural plasticity.
Neuroplasticity refers to the nervous system's ability to adapt through changes in neural connections and function.
However, laboratory findings do not demonstrate that MDMA produces lasting beneficial brain changes in humans.
Claims about permanent neurological repair or brain rewiring are not supported by current clinical evidence.
8. MDMA Safety, Contraindications and Medication Interactions
Is MDMA safe in a clinical research environment?
Controlled research environments provide screening, monitoring and defined safety procedures.
These measures can help identify and manage certain risks.
Nevertheless, MDMA can cause adverse physiological and psychological effects even in supervised conditions.
Clinical participation should not be described as risk-free.
What are the main physical risks of MDMA?
Known acute risks include increased blood pressure, elevated heart rate, increased body temperature and disturbances in fluid or electrolyte balance.
Other possible effects include nausea, jaw tension, headache and reduced appetite.
The severity and likelihood of adverse effects depend on individual circumstances and the context of exposure.
Why does cardiovascular health matter?
MDMA can stimulate the cardiovascular system.
People with certain heart conditions, uncontrolled hypertension or other cardiovascular risk factors may face increased risks.
Clinical trials therefore commonly include cardiovascular screening and exclusion criteria.
Can MDMA interact with antidepressants?
Yes.
Some antidepressants can alter MDMA's pharmacological effects, while certain combinations may create significant safety concerns.
Monoamine oxidase inhibitors are particularly important because of potentially dangerous interactions.
The implications of other antidepressants depend on their pharmacological properties.
Medication should never be discontinued or adjusted independently to participate in psychedelic research.
Why are MAO inhibitors particularly concerning?
MAO inhibitors interfere with the breakdown of certain neurotransmitters.
Combining MAO-inhibiting drugs with MDMA can produce dangerous interactions, including excessive serotonergic activity.
These interactions are a major consideration in clinical research screening.
What about benzodiazepines such as diazepam?
Benzodiazepines influence the central nervous system and can affect the psychological response to psychoactive substances.
Their use may be restricted or carefully evaluated in research protocols.
Long-term benzodiazepine treatment also requires caution because abrupt discontinuation can cause serious withdrawal symptoms.
Can prescribed stimulants interact with MDMA?
Potentially.
Some prescribed stimulants can increase sympathetic nervous system activity.
Combining stimulants with MDMA may increase cardiovascular or other physiological risks.
Medication interactions require assessment within an appropriate clinical framework.
Is body weight relevant in MDMA research?
Body weight can influence drug exposure and is sometimes considered in research protocols.
Some clinical studies have used minimum or maximum weight criteria.
However, body weight is only one factor among many, including individual physiology, medical history and medication use.
It does not independently establish a safe amount or guarantee suitability.
Do genetics affect the metabolism of MDMA?
Genetic differences in drug-metabolizing enzymes may influence MDMA exposure.
CYP2D6 is one enzyme involved in MDMA metabolism, although MDMA itself also inhibits this enzyme.
Other metabolic pathways and individual factors contribute to its overall pharmacology.
Pharmacogenetic testing cannot reliably predict the complete psychological or physiological response to MDMA.
Can MDMA affect sleep after administration?
Yes.
Sleep disturbances, fatigue and changes in mood have been reported following MDMA exposure.
The duration and severity vary between individuals.
These effects are relevant when researchers assess post-session recovery and adverse events.
Are there risks related to sodium and hydration?
Yes.
MDMA may affect fluid regulation and, under certain circumstances, contribute to dangerously low blood sodium concentrations.
Both excessive water consumption and disturbances in normal physiological regulation can be relevant.
This is one reason why clinical protocols include physiological monitoring and safety procedures.
Can MDMA cause serotonin syndrome?
MDMA has serotonergic effects and may contribute to serotonin toxicity, particularly when combined with certain medications or other serotonergic substances.
Severe serotonin toxicity is a medical emergency.
The potential for dangerous interactions is an important part of research screening.
Are people with bipolar disorder or psychosis included in MDMA trials?
Clinical studies commonly apply exclusions or additional precautions involving certain psychiatric histories, particularly conditions associated with mania or psychosis.
The exact criteria vary.
Research findings from selected participants should not be applied automatically to people excluded from those studies.
Why are professional boundaries important in MDMA research?
MDMA may influence feelings of trust, closeness and emotional vulnerability.
This creates particular ethical responsibilities for professionals involved in research.
Informed consent, clear boundaries, safeguarding, appropriate supervision and procedures for reporting misconduct are essential.
Research participation never removes a person's right to bodily autonomy or respectful treatment.
8. MDMA Compared With Other Psychoactive Substances
What is the difference between MDMA and psilocybin?
MDMA is primarily an entactogen with stimulant properties.
Psilocybin is a classical serotonergic psychedelic.
Their principal pharmacological mechanisms and characteristic subjective experiences differ.
Scientific research into one substance cannot be assumed to establish the same effects or clinical outcomes for the other.
Is MDMA more emotionally focused than psilocybin?
MDMA is often associated with changes in emotional openness and interpersonal feelings.
Psilocybin more commonly produces pronounced alterations in perception, thought patterns and consciousness.
However, individual experiences vary considerably, and these general characteristics cannot predict a particular person's response.
Has the combination of MDMA and psilocybin been studied?
There is substantially less clinical evidence for combined MDMA and psilocybin administration than for either substance individually.
Findings from separate MDMA and psilocybin trials cannot simply be combined to predict the effects of simultaneous administration.
What are MDMA analogues?
MDMA analogues are chemically related substances that may share some pharmacological or subjective characteristics with MDMA.
Examples include MDA, MDEA, 5-MAPB, 6-APB and methylone.
These compounds differ in their molecular structure and pharmacology.
They should not be considered interchangeable with genuine MDMA.
Did MAPS use MDMA analogues in its pivotal PTSD studies?
No.
The pivotal MAPS-sponsored PTSD trials investigated genuine pharmaceutical-grade MDMA.
Their findings cannot be used to claim equivalent clinical effectiveness or safety for other MDMA-like compounds.
Has methylone been investigated clinically?
Yes.
A randomized phase 2 study published in JAMA Psychiatry in 2026 investigated TSND-201, a pharmaceutical formulation of methylone, in 65 participants with PTSD.
The findings supported further research.
However, methylone is a distinct substance, and its clinical evidence cannot be generalized to other analogues.
Are MDMA analogues safer than MDMA?
There is insufficient evidence to make that general claim.
Some analogues have received limited human research, while others remain poorly characterized.
Chemical similarity does not guarantee equivalent safety, duration or therapeutic effects.
Can an analogue have different long-term consequences?
Yes, potentially!
Differences in receptor activity, metabolism and physiological effects may influence the long-term risk profile.
For many designer drugs, reliable longitudinal human studies are unavailable.
The absence of documented harm is not proof that a substance is safe.
10. Legal Status, Regulation and Future Research
Is MDMA-assisted psychotherapy approved in the United States?
The FDA declined to approve the 2024 application for MDMA-assisted treatment of PTSD.
Further regulatory activity was reported in 2026, but an application or resubmission does not itself constitute approval.
The approval status should be checked through official FDA information.
Is MDMA prescribed medically in Australia?
Australia introduced a restricted regulatory pathway allowing specifically authorised psychiatrists to prescribe MDMA for PTSD under defined conditions.
This arrangement does not constitute unrestricted access or proof of effectiveness for all psychiatric conditions.
Other countries have different regulatory frameworks.
Can anyone participate in an MDMA clinical trial?
No.
Clinical trials have defined inclusion and exclusion criteria.
Factors such as age, diagnosis, medical history, medication use and psychiatric stability may influence eligibility.
Eligibility decisions are determined by the research team operating under an approved protocol.
Scientific References and Further Reading
-
Sevchik et al. (2026). A living systematic review, meta-analysis, and open data resource of trials of MDMA-assisted therapy for PTSD. Neuropsychopharmacology.
https://www.nature.com/articles/s41386-026-02575-z -
Mitchell et al. (2023). MDMA-assisted therapy for moderate to severe PTSD: A randomized, placebo-controlled phase 3 trial. Nature Medicine.
https://www.nature.com/articles/s41591-023-02565-4 -
State of the Science: MDMA-assisted psychotherapy for the treatment of posttraumatic stress disorder (2026). Journal of Traumatic Stress.
https://pubmed.ncbi.nlm.nih.gov/41820235/ -
MDMA-assisted therapy for social anxiety disorder: A randomized, open-label, wait-list controlled trial (2026).
https://pubmed.ncbi.nlm.nih.gov/42994762/ -
Kvam et al. (2025). MDMA-assisted therapy as a treatment for major depressive disorder: Proof-of-principle study.
https://pubmed.ncbi.nlm.nih.gov/40641116/ -
Changes in wellbeing, self-compassion and alexithymia in MDMA-assisted therapy for major depressive disorder (2026).
https://pubmed.ncbi.nlm.nih.gov/43008413/ -
Efficacy and Safety of TSND-201 (Methylone) for PTSD: A Randomized Clinical Trial (2026). JAMA Psychiatry.
https://jamanetwork.com/journals/jamapsychiatry/fullarticle/2844885 -
European Union Drugs Agency. Frequently Asked Questions: Therapeutic Use of Psychedelic Substances.
https://www.euda.europa.eu/publications/frequently-asked-questions-faq/faq-therapeutic-use-psychedelic-substances_en -
US Food and Drug Administration. Complete Response Letter for Midomafetamine, August 2024.
https://download.open.fda.gov/crl/CRL_NDA215455_20240808.pdf -
Government of the Netherlands. State Commission on MDMA and Potential Therapeutic Applications.
https://www.rijksoverheid.nl/actueel/nieuws/2024/06/06/staatscommissie-mdma-ziet-mogelijkheden-voor-therapeutische-toepassing-mdma -
Netherlands Government: Parliamentary Answers Concerning Psychedelic Research, September 2026.
https://zoek.officielebekendmakingen.nl/ah-tk-20252026-2917.html
Educational and Scientific Disclaimer
This publication is intended exclusively for educational purposes and general discussion of scientific research.
It does not promote, recommend, advertise or encourage the consumption of MDMA, MDMA analogues or other controlled psychoactive substances.
The information does not constitute medical advice, an offer of treatment or a recommendation to change prescribed medication.
Scientific findings discussed here do not establish that MDMA can cure, prevent or reliably treat PTSD, complex PTSD, depression, anxiety disorders or other medical or psychiatric conditions.
All reported clinical outcomes relate to their respective study populations, research methods and assessment periods.
No specific treatment outcome or individual safety profile can be guaranteed.
Add comment
Comments